In the United States, the Centers for Disease Control and Prevention (CDC) has stopped its support for an anti-viral drug called “GCL” in the United Kingdom after a two-week outbreak in England.
The decision was announced by Dr. Peter McEwen, director of the CDC’s National Center for Infectious Diseases.
In a statement released by the CDC, Dr. McEwin said the agency “strongly advises against all new and existing GCL use.”
The CDC said the decision was made after reviewing the data on GCL’s use in England and a study by researchers at the University of Manchester.
“It is the position of the United Nations Committee on the Elimination of all Forms of Discrimination Against Women that GCL is a prohibited product under the Convention on the Rights of the Child and should be withdrawn from the market,” Dr. James C. Miller, the committee’s deputy chair, said in the statement.
“In accordance with that understanding, the United Nation’s High Commissioner for Human Rights (OHCHR) has requested that the WHO review the circumstances under which GCL should be banned.”
The announcement came a week after a similar ban was put in place in the UK.
The United States is the only country that has approved GCL.
The FDA has not said if the United State will allow the drug to be sold.
A similar ban has been placed in place by the EU and the UK for similar drugs.
The ban comes just one day after the US Food and Drug Administration (FDA) announced that it was banning GCL from the United Arab Emirates, Bahrain, Saudi Arabia, Kuwait, Qatar, the UAE and Qatar.
A spokesperson for the FDA said that Gcl is not approved in the US because it is a “known carcinogen.”
The agency also said that the drug is associated with a risk of cancer.
According to a statement by the FDA, Gcl’s “exposure-dependent and cumulative toxicities are well known and may cause serious long-term adverse health effects including lung, liver, and brain damage.”
The FDA did not respond to a request for comment from Medical News Online.
GCL was originally approved for use in the Netherlands in the mid-1990s and is approved in Europe and the United states.
It has been approved in other countries around the world.
The drug was first licensed in the U.K. in 2009 and became available in the EU in July 2014.
Gcl can be prescribed to patients for the treatment of HIV/AIDS, malaria, cancer, asthma and other chronic illnesses.
The drugs are available through pharmacies across the country and can cost up to $30,000.
In August, the CDC announced that there was a second GCL case in the country of Denmark.
The first case, an Australian woman, was diagnosed with a rare form of the virus.
The new case is believed to be the same as the Australian woman who tested positive in London, which was confirmed on Sunday.
A spokesman for the CDC said that there is no evidence that the new patient had received GCL in the past.
The CDC also noted that the second case may have been infected while using GCL and that the two cases were in different locations and could have come from different people.
A GCL spokesperson said that they have since tested all the patients who received Gcl.
A second case in Denmark was diagnosed on Saturday.
The second case, who was not treated, was admitted to a hospital on Saturday with the infection.
The spokesman said that both cases are in the hospital with fever and were receiving care.
It is not yet known if GCL will be approved in Australia and the U,K., and if it will be banned from the US.
